Showing 5131-5140 of 5771 results for "".
- Harrow Health to Locate Headquarters in Nashville, Tennesseehttps://modernod.com/news/harrow-health-to-locate-headquarters-in-nashville-tennessee/2476667/Harrow Health announced that the company will relocate its headquarters from San Diego to Nashville, Tennessee. “From our new home in Nashville, our team will continue to start, finance and grow pharmaceutical companies that will develop innovative, affordable and accessible medicines to s
- NovaBay Pharmaceuticals Appoints Justin Hall President and CEO, and Jason Raleigh CFOhttps://modernod.com/news/novabay-pharmaceuticals-appoints-justin-hall-president-and-ceo-and-jason-raleigh-cfo/2476666/NovaBay Pharmaceuticals announced the appointments of Justin Hall as President and Chief Executive Officer, and Jason Raleigh as Chief Financial Officer. Mr. Hall has served as interim President and CEO, and Mr. Raleigh as interim CFO since March 2019. “Justin and Jason have proven their l
- Be The Match BioTherapies and TrakCel Partner to Standardize Cell and Gene Therapy Supply Chain Solutionshttps://modernod.com/news/be-the-match-biotherapies-and-trakcel-partner-to-standardize-cell-and-gene-therapy-supply-chain-solutions/2476662/Be The Match BioTherapies and TrakCel, a software developer for cell and gene therapy supply chain tracking and orchestration systems, announced a collaboration that will provide integrated solutions for companies develo
- Eyepromise Introduces Screen Shield Pro All-Natural Eye Vitamin for Screen Time Protection for Adultshttps://modernod.com/news/eyepromise-introduces-screen-shield-pro-all-natural-eye-vitamin-for-screen-time-protection-for-adults/2476661/EyePromise announced the introduction of Screen Shield Pro to its premium eye vitamin line. EyePromise’s Screen Shield Pro is designed to protect and relieve the associated symptoms of digital eye strain of adults (ages 18 and up) who spend 8+ hours staring at digital screens while working, gami
- Pre-Pilot Clinical Trial from Ocutrx Vision Technologies Yields Exciting Results for Patients with AMDhttps://modernod.com/news/pre-patient-trial-from-ocutrx-vision-technologies-yields-exciting-results-for-patients-with-amd/2476659/Ocutrx Vision Technologies announced the results of the first pre-pilot clinical trial for the company’s Oculenz AR glasses. In the single arm crossover study of subjects with advanced macular degeneration, the Oculenz AR glasses significantly improved the ability of subjects to read small letter
- Valeda Light Delivery System Receives 2019 Medical Design Excellence Awardhttps://modernod.com/news/valeda-light-delivery-system-receives-2019-medical-design-excellence-award/2476654/LumiThera and Product Creation Studio announced that LumiThera’s Valeda Light Delivery System has won a silver award in the 21st Annual Medical Design Excellence Awards competition. The 2019 winners were announced at the MDEA Ceremony on Tuesday, June 11, 2
- First Patient Dosed in Phase 2 Trial Evaluating Ocular Delivery of ST266 For the Treatment of Persistent Corneal Epithelial Defectshttps://modernod.com/news/noveome-biotherapeutics-announces-the-first-patient-dosed-in-phase-2-open-label-clinical-trial-evaluating-topical-ocular-delivery-of-st266-for-the-treatment-of-persistent-corneal-epithelial-defects/2476652/Noveome Biotherapeutics announced the dosing of the first patient in its phase 2 open label, multicenter clinical trial evaluating topical ocular delivery of ST266 for the treatment of persistent corneal epithelial defects (PEDs), for which there are limited treatment options. “The dosing
- First Subject Enrolled in Trial to Confirm Safety and Efficacy of TearCare Device for Dry Eyehttps://modernod.com/news/first-subject-enrolled-in-large-trial-to-confirm-safety-and-efficacy-of-dry-eye-treatment-device-tearcare/2476650/Sight Sciences announced the first subject has been enrolled in OLYMPIA, a US pivotal trial to further assess the safety and efficacy of TearCare for patients with dry eye disease. TearCare is a wearable, personalized, open-eye technology that delivers regu
- OcuSoft Introduces NEW OcuSoft Lid Scrub Allergy Eyelid Treatment for Red, Itchy Allergy Eyeshttps://modernod.com/news/ocusoft-introduces-new-ocusoft-lid-scrub-allergy-eyelid-treatment-for-red-itchy-allergy-eyes/2476646/OcuSoft announced the availability of new OcuSoft Lid Scrub Allergy Eyelid Cleanser for allergy conditions in convenient pre-moistened pads. OcuSoft Lid Scrub Allergy removes oil, debris, pollen and other contaminants from the eyelids while utilizing Green Tea Extract, Tea Tree Oil and PSG
- A Single Course of Provention’s PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least 2 Yearshttps://modernod.com/news/a-single-course-of-proventions-prv-031-teplizumab-delays-type-1-diabetes-onset-in-high-risk-individuals-by-at-least-2-years/2476644/Provention Bio announced that results from the National Institutes of Health (NIH)-sponsored “At-Risk” Study were published on-line in The New England Journal of Medicine and presented at the Scientific Sessions of the 79th Annual American Diabetes Association (ADA) meeting.